JP Morgan Maintains Overweight on TransMedics Gr, Raises Price Target to $127
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Allen Gong maintains an Overweight rating on TransMedics Group (TMDX) and raises the price target from $105 to $127.
May 01, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Allen Gong reaffirmed an Overweight rating on TransMedics Group, Inc. (TMDX) and increased the price target from $105 to $127.
The increase in price target by a reputable analyst like Allen Gong from JP Morgan suggests a strong confidence in TransMedics Group's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in TMDX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100